Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Real Time Quote from BATS)

$4.38 USD

4.38
1,410,361

+0.25 (6.05%)

Updated Aug 25, 2026 03:48 PM ET

After-Market: $4.38 0.00 (0.00%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moving Average Crossover Alert: Ironwood Pharmaceuticals

by Zacks Equity Research

Ironwood Pharmaceuticals, Inc. (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Pacira's Late-Stage Study on Exparel Label Expansion Positive

by Zacks Equity Research

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Zacks Equity Research

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

by Zacks Equity Research

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

Zacks Equity Research

Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for December 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

Zacks Equity Research

Catalyst Focuses on Firdapse Label Expansion Amid Competition

by Zacks Equity Research

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

Zacks Equity Research

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics

Nalak Das headshot

5 Best-Performing, Top-Ranked Growth Stocks of November

by Nalak Das

Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical